Safety Prediction for Pre 1988 Permitted Fixed Dose Combinations Using Artificial Intelligence - In Silico Approach
DOI:
https://doi.org/10.55940/medphar2025107Keywords:
Artificial Intelligence, Drug Combinations, Drug-Related Side Effects, SwissADME, vNN-ADMET, AERSMineAbstract
Background: Since the Drug Controller General of India (DCGI) approved more than 130 FDCs, the usage of fixed dose combinations (FDCs) has become more popular. FDCs are medications that contain more than one active component, aiming to enhance adherence, reduce adverse effects, and improve effectiveness. In a recent development, the Central Drug Standard Control Organisation (CDSCO) issued a notice on January 11, 2024, calling for the evaluation of pre-1988 permitted FDCs.
Objective: This study aimed to determine whether AI algorithms could predict the safety of FDCs by examining their pharmacokinetic properties.
Methods: In order to assess pharmacokinetic properties and verify the safety of pre-1988 permitted fixed dose combinations that were approved by The Central Drug Standard Control Organisation, India (CDSCO), this study used a range of AI tools, including ADMET.AI, SwissADME, vNN-ADMET, and AERSMine.
Results: The results made by these tools were giving dissimilar properties in the same drug combinations. So, these tools are presently needs to be developed to have more accurate and precise results.
Conclusion: This research contributes to the ongoing discourse surrounding FDCs, pharmaceutical innovation, and regulatory practices, providing valuable insights that can shape future approaches in drug development and patient care with the help of artificial intelligence and data-based analysis tools. Additionally, this work helps to strengthen the credibility of the current A.I. development for in-silico pharmacokinetic predictions.
References
Rana S, Prakash P. In-Silico Pharmacokinetic Prediction for New Fixed Dose Combinations-A Lesson to Learn. Inven. Rapid Pharmacokinet. Pharmacodyn. 2021 ;(4):0–8.
Rana S, Prakash P. Therapeutic Rationality of Recently Approved Fixed Dose Combinations by CDSCO-A Post Ban Analysis. Inventi Rapid: Pharmacy Practice. 2021 ;( 2):1-5.
Boretti A. Curcumin-based fixed dose combination products for cholesterol management: a narrative review. ACS Pharmacology & Translational Science. 2024; 7(2):300-8. DOI: 10.1021/acsptsci.3c00234
Sepanlou SG, Mann JF, Joseph P, Pais P, Gao P, Sharafkhah M, Roshandel G, Yusuf S, Malekzadeh R, Polypill Trialists' Collaboration. Fixed-dose combination therapy for the prevention of cardiovascular diseases in CKD: an individual participant data meta-analysis. Clinical Journal of the American Society of Nephrology. 2023; 18(11):1408-15. DOI: 10.2215/CJN.0000000000000251.
Bahiru E, de Cates AN, Farr MR, Jarvis MC, Palla M, Rees K, Ebrahim S, Huffman MD. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. The Cochrane database of systematic reviews. 2017; 3(3):CD009868. DOI: 10.1002/14651858.CD009868.pub3.
Central Drugs Standard Control Organization. Policy guidelines for approval of fixed dose combination (FDCs) in India. June, 2013, Available at http://www.mohfw.nic.in/WriteReadData/l892s/6404452866Kokate Report.pdf. Access Date- 15 January 2025.
World Health Organization. Annex 5 Guidelines for registration of fixed dose. WHO Tech Rep Ser. 2005, Available at TRS 929 - Annex 5: Guidelines for registration of fixed-dose combination medicinal products Access Date- 15 January 2025.
Agarwal A, Mehta PM, Jacobson T, Shah NS, Ye J, Zhu J, Wafford QE, Bahiru E, de Cates AN, Ebrahim S, Prabhakaran D. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease. Nature medicine. 2024; 30(4):1199-209. DOI: 10.1038/s41591-024-02896-w
Wilkins CA, Hamman H, Hamman JH, Steenekamp JH. Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features. Pharmaceutics. 2024; 16(2):178. DOI: 10.3390/pharmaceutics16020178.
DCGI. Fixed Dose Combinations Approved By DCGI. 2021, Available at https://cdsco.gov.in/opencms/opencms/en/Approval_new/FDC-New-Drugs-Marketing. Access Date- 15 January 2025.
Hu Z, Xiao X, Zhang G, Li Y. Revolutionizing Fixed-Dose Combinations with Long-Acting Microsphere. European Journal of Pharmaceutical Sciences. 2025 Feb 4:107032.
DCGI. FIXED DOSE COMBINATIONS APPROVED BY DCG (I) From January 2023 to December 2023. 2023, Available at cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTEwMjc=. Access Date- 15 January 2025.
Murphy A, Mbuthia D, Willis R, Tsofa B, Gichagua M, Mugo P, Hanson K, Reich MR. Improving Implementation of NCD Care in Low-and Middle-Income Countries: The Case of Fixed Dose Combinations for Hypertension in Kenya. Health Systems & Reform. 2025; 11(1):2448862. DOI: 10.1080/23288604.2024.2448862.
Vignesh M, Ganesh GN. Fixed dose combinations banned in India-a review. J Pharm Sci Rev. 2020; 12(7):987-91.
Jain NK, Akarte A, Deshmukh PT, Kannojia P, Garud N, Yadav A. Rationality of fixed dose combinations: an Indian scenario. Pharma Res. 2009;1(1):158-68.
Wangnoo SK, Bhadada SK, Farishta F, Jayaram Naidu GG, Pattnaik I, Manohar KN, Singh KP, Gupta SK, Bharath HS, Ghosh S. Safety and efficacy of fixed-dose combination of dapagliflozin and saxagliptin in patients with type 2 diabetes mellitus–a phase 4 study in India. Frontiers in Endocrinology. 2025; 16:1528801. DOI:10.3389/fendo.2025.1528801
Indian Pharmaceuticals Industry Analysis Presentation | IBEF. 2023, Available at https://www.ibef.org/industry/indian-pharmaceuticals-industry-analysis-presentation%0A*. Access Date- 15 January 2025.
Mazumdar M, Mazumdar M. An overview of the Indian pharmaceutical sector. Performance of pharmaceutical companies in India: A critical analysis of industrial structure, firm specific resources, and emerging strategies. 2013:17-44. DOI: 10.1007/978-3-7908-2876-4_2
McGettigan P, Roderick P, Mahajan R, Kadam A, Pollock AM. Use of fixed dose combination (FDC) drugs in India: central regulatory approval and sales of FDCs containing non-steroidal anti-inflammatory drugs (NSAIDs), metformin, or psychotropic drugs. PLoS Med. 2015; 12(5):e1001826. DOI: 10.1371/journal.pmed.1001826.
Central Drugs Standard Control Organization. Evaluation of certain pre 1988 permitted Fixed Dose Combinations. 2024, Available at https://cdsco.gov.in/opencms/opencms/en/Drugs/FDC/. Access Date- 15 January 2025.
Swanson K, Walther P, Leitz J, Mukherjee S, Wu JC, Shivnaraine RV, Zou J. ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. Bioinformatics. 2024; 40(7):btae416. DOI: 10.1101/2023.12.28.573531
ADMET.AI. Greenstone Biosciences and Prof. James Zou's lab at Stanford University. Available at https://admet.ai.greenstonebio.com/. Access Date- 15 January 2025.
Murphy A, Mbuthia D, Willis R, Tsofa B, Gichagua M, Mugo P, Hanson K, Reich MR. Improving Implementation of NCD Care in Low-and Middle-Income Countries: The Case of Fixed Dose Combinations for Hypertension in Kenya. Health Systems & Reform. 2025 Dec 31;11(1):2448862. DOI:10.1080/23288604.2024.2448862
Fadilah A, Putri VYS, Puling IMDR, Willyanto SE. Assessing the precision of machine learning for diagnosing pulmonary arterial hypertension: a systematic review and meta-analysis of diagnostic accuracy studies. Front Cardiovasc Med. 2024 Aug 27;11:1422327. DOI: 10.3389/fcvm.2024.1422327.
Catacutan DB, Alexander J, Arnold A, Stokes JM. Machine learning in preclinical drug discovery. Nature Chemical Biology. 2024; 20(8):960-73.
ATC/DDD Index 2024, Norwegian Institute of Public Health NIPH. Available at https://atcddd.fhi.no/atc_ddd_index/. Access Date- 15 January 2025.
Sarangdhar M, Tabar S, Schmidt C, Kushwaha A, Shah K, Dahlquist JE, Jegga AG, Aronow BJ. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nature biotechnology. 2016 ;34(7):697-700.
AERSMine. Available at https://research.cchmc.org/aers/. Access Date- 15 January 2025.
Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017 Aug;60:1385-9.
Giunchi V, Fusaroli M, Hauben M, Raschi E, Poluzzi E. Challenges and opportunities in accessing and analysing FAERS data: a call towards a collaborative approach. Drug Safety. 2023 ;46(10):921-6.
Jiang A, Jegga AG. Characterizing drug-related adverse events by joint analysis of biomedical and genomic data: A case study of drug-induced pulmonary fibrosis. AMIA Summits on Translational Science Proceedings. 2018; 2018:91.
Borrelli EP, Lee EY, Caffrey AR. Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program. Ment Health Clin. 2020 May 7;10(3):70-75. doi: 10.9740/mhc.2020.05.070. Schyman P, Liu R, Desai V, Wallqvist A. vNN web server for ADMET predictions. Frontiers in pharmacology. 2017 ;8:889.
Kar S, Roy K, Leszczynski J. In silico tools and software to predict ADMET of new drug candidates. Inin silico methods for predicting drug toxicity 2022 Feb 21 (pp. 85-115). New York, NY: Springer US.
Vnn-ADMET Telemedicine and Advanced Technology Research Center (TATRC) and US Army Medical Research and Development Command (USAMRDC). https://vnnadmet.bhsai.org/vnnadmet/login.xhtml. Access Date- 15 January 2025.
Kar S, Leszczynski J. Open access in silico tools to predict the ADMET profiling of drug candidates. Expert opinion on drug discovery. 2020; 15(12):1473-87.
Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic acids research. 2021; 49(W1):W5-14.
Krishnaveni K, Sabitha M, Murugan M, Kandeepan C, Ramya S, Loganathan T, Jayakumararaj R. vNN model cross validation towards Accuracy, Sensitivity, Specificity and kappa performance measures of β-caryophyllene using a restricted-unrestricted applicability domain on Artificial Intelligence & Machine Learning approach based in-silico prediction. Journal of Drug Delivery and Therapeutics. 2022; 12(1-S):123-31.
Bakchi B, Krishna AD, Sreecharan E, Ganesh VB, Niharika M, Maharshi S, Puttagunta SB, Sigalapalli DK, Bhandare RR, Shaik AB. An overview on applications of SwissADME web tool in the design and development of anticancer, antitubercular and antimicrobial agents: A medicinal chemist's perspective. Journal of Molecular Structure. 2022; 1259:132712. DOI: 10.1016/j.molstruc.2022.132712
Afridi MB, Sardar H, Serdaroğlu G, Shah SWA, Alsharif KF, Khan H. SwissADME studies and Density Functional Theory (DFT) approaches of methyl substituted curcumin derivatives. Comput Biol Chem. 2024; 112:108153. DOI: 10.1016/j.compbiolchem.2024.108153.
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports. 2017; 7(1):42717. DOI:10.1038/srep42717
Gangadhar Y, Al Turaifi AR, Naveen NR, Goudanavar P, Fattepur S, Sreeharsha N, Islam MM, Chohan MS. Bio-Simulation Studies of Valganciclovir Hydrochloride: Molecular Descriptor-Based QSAR Modelling and Swiss ADME Analysis Using in silico Models. Indian Journal of Pharmaceutical Education and Research. 2025;59(1s):s132-7. DOI:10.5530/ijper.20251137
Rauf A, Khan H, Khan M, Abusharha A, Serdaroğlu G, Daglia M. In Silico, SwissADME, and DFT Studies of Newly Synthesized Oxindole Derivatives Followed by Antioxidant Studies. Journal of Chemistry. 2023; 2023(1):5553913. DOI:10.1155/2023/5553913
Mahanthesh MT, Ranjith D, Yaligar R, Jyothi R, Narappa G, Ravi MV. Swiss ADME prediction of phytochemicals present in Butea monosperma (Lam.) Taub. Journal of Pharmacognosy and Phytochemistry. 2020;9(3):1799-809.
Ranjith D, Ravikumar C. SwissADME predictions of pharmacokinetics and drug-likeness properties of small molecules present in Ipomoea mauritiana Jacq. Journal of Pharmacognosy and Phytochemistry. 2019;8(5):2063-73.
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic acids research. 2018 ;46(D1):D1074-82. DOI: 10.1093/nar/gkx1037
Daina A, Zoete V. Application of the SwissDrugDesign Online Resources in Virtual Screening. Int J Mol Sci. 2019 Sep 18;20(18):4612. DOI: 10.3390/ijms20184612.
Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, Pon A, Cox J, Chin NE, Strawbridge SA, Garcia-Patino M. DrugBank 6.0: the DrugBank knowledgebase for 2024. Nucleic acids research. 2024 ;52(D1):D1265-75. DOI: 10.1093/nar/gkad976
Cuesta SA, Mora JR, Márquez EA. In silico screening of the DrugBank database to search for possible drugs against SARS-CoV-2. Molecules. 2021; 26(4):1100. DOI: 10.3390/molecules26041100
Rana S, Sharma N, Dutt S, Patil RD, Rana D. Histological Investigation to Verify the Protective Advantages of Carissa Spinarum Leaves Extract in Zebrafish (Danio rerio). Med Pharm J. 2025; 3(4):160-71. DOI: 10.55940/medphar202499
Rana S, Sharma N, Dutt S, Patil R. Hepatoprotective Effects of Carissa spinarum Extract on Carbon Tetra Chloride Induced Liver Damage in Zebrafish (Danio rerio). Med Pharm J. 2023 ;2(4):206-20. DOI: 10.55940/medphar202362
Bischoff K, Mukai M, Ramaiah SK. Liver toxicity. InVeterinary toxicology 2018 Jan 1 (pp. 239-257). Academic Press.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Shiwank Rana, Ajay Singh, Deepika
This work is licensed under a Creative Commons Attribution 4.0 International License.
